Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
3 min
1. Editor's foreword- Prof. Ann Daly
-
47 min
2. Introduction to drug metabolism enzymes- Dr. Dennis Smith
- General factors affecting drug metabolism
-
30 min
3. General factors affecting drug metabolism: effect of physiological factors and disease 1- Prof. Edward T. Morgan
-
24 min
4. General factors affecting drug metabolism: effect of physiological factors and disease 2- Prof. Edward T. Morgan
-
39 min
5. Drug metabolism in liver disease- Dr. Nathalie Zgheib
- Prof. Robert Branch
-
37 min
-
50 min
7. Prediction of pathways of drug metabolism- Dr. Maurice Dickins
- Phase I metabolizing enzymes: cytochrome P450s
-
45 min
8. Cytochrome P450 1 family: the roles of 1A1, 1A2 and 1B1 in drug metabolism- Prof. F. Peter Guengerich
-
42 min
9. CYP2 family- Prof. Ann Daly
-
52 min
10. Why study the cytochrome P4503A (CYP3A) family?- Dr. Erin Schuetz
-
54 min
11. Pharmacogenomics: an update- Prof. Magnus Ingelman-Sundberg
- Phase I metabolizing enzymes: non-cytochrome P450s
-
45 min
12. Non-P450 oxidative metabolism: characteristics and drug substrates- Dr. Christine Beedham
-
53 min
13. UDP-glucuronosyltransferases- Prof. Abby Collier
- Phase II metabolizing enzymes: conjugating enzymes
-
31 min
14. Glutathione transferases- Prof. Ralf Morgenstern
-
31 min
15. Arylamine N-acetyltransferases 1- Prof. Edith Sim
-
23 min
16. Arylamine N-acetyltransferases 2- Prof. Edith Sim
-
19 min
17. Arylamine N-acetyltransferases 3- Prof. Edith Sim
-
56 min
18. Methyltransferases- Prof. Richard Weinshilboum
-
22 min
19. Amino acid conjugation: mechanism and enzymology- Dr. Kathleen Knights
- Clinical aspects
-
33 min
20. Clinical significance of enzyme induction and inhibition- Prof. Kim Brøsen
-
39 min
21. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism- Prof. Julia Stingl (formerly Kirchheiner)
- Latest Updates in the Field
-
34 min
22. Mammalian flavin-containing monooxygenases- Prof. Allan Rettie
- Archived Lectures *These may not cover the latest advances in the field
-
54 min
23. Glucuronidation and the UDP - glucuronosyltransferases- Prof. Peter Mackenzie
- Prof. John Miners
-
38 min
-
28 min
25. Catalytic cycle of cytochrome P450s- Prof. Gordon Roberts
-
40 min
26. Drug metabolism and liver disease- Prof. Robert Branch
-
46 min
27. Crystal structures of drug-metabolizing P450 monooxygenases- Prof. Eric Johnson
-
49 min
28. Sulfation and human cytosolic sulfotransferases- Prof. Charles Falany
-
50 min
29. Laboratory methods for the in vitro study of drug metabolism- Dr. Charles Crespi
-
45 min
30. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain- Prof. Julia Stingl (formerly Kirchheiner)
-
51 min
-
53 min
32. Pharmacogenomics- Prof. Magnus Ingelman-Sundberg
Printable Handouts
Navigable Slide Index
- Genetic variability in PON1
- PON1 in health and disease
- Goals of presentation
- Origin of paraoxonase name
- Serum PON1 activity
- PON1 polymorphisms
- Additional PON1 SNPs discovered
- Properties of human PON1
- P450-PON pathway for detoxification
- PON1 genetic variability - conseq.
- Determination of PON1 status
- PON1 function in rodent models
- Increased plasma levels of PON1
- High PON1 levels protection
- Low PON1 levels - consequences
- PON1 +/+, +/-, -/- activity levels
- Chlorpyrifos oxon - PON1 +/+, -/-
- Diazoxon - PON1 +/+, +/-, -/-
- Paraoxon - PON1 +/+, +/-, -/-
- In vivo efficacy of PON1 detox.
- Young individuals and OP sensitivity
- Dev. onset of PON1 activity in child.
- Mouse lines carrying human PON1
- hPON1 activity - in Q192/R192 mice
- Sensitivity to CPO toxicity
- Chlorpyrifos oxon exposure
- OP pesticide exposure - conseq.
- Role of PON1192 polymorphism
- Mixed exposures
- Chlorpyrifos oxon/malaoxon expos.
- PON1 mutants - PBPK/PD
- PBPK simulation of AChE activities
- Test of model in PON1 -/- mice
- Genetically variable PON1 status
- PON1 status availability
- Impacts of PON1 genetic variations
- PON1 in health and disease
- Physiological role of PON1
- PON1 activity levels
- PON1 in health and disease
- Important lactone substrates
- Enzymatic activities of hPONs
- Paraoxonases - drug inactiv./activ.
- PON1 in health and disease
- Hydrolysis of 3-O-HSL by PONs
- Avenues of expl. in PON1 KO mice
- OPs detoxication in PON1 KO mice
- The bottom line
- Summary
- PON1 collaborators
- References from the author (1)
- References from the author (2)
- References from the author (3)
Topics Covered
- Paraoxonase (PON1)
- Hydrolytic reactions
- Enzyme properties
- Polymorphisms
- Use of mouse models
- PON1 levels in human populations
- PON1 status as a risk factor in carotid artery disease
- Designing epidemiological studies for examining PON1 genetic variability and risk
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Furlong, C. (2007, October 1). Genetic variability in Paraoxonase 1 (PON1), an HDL associated esterase: impact on risk and pharmacokinetics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 13, 2025, from https://doi.org/10.69645/BMYL4915.Export Citation (RIS)
Publication History
Financial Disclosures
- Res. Prof. Clement Furlong has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Genetic variability in Paraoxonase 1 (PON1), an HDL associated esterase: impact on risk and pharmacokinetics
A selection of talks on Pharmaceutical Sciences
Hide